跳至主要内容
临床试验/IRCT20130921014727N7
IRCT20130921014727N7已完成4 期

The Pilot Study of Efficacy and Safety of Cyproheptadine in Pulmonary Arterial Hypertension Patients in Massih Daneshvari Hospital

Faculty of Pharmacy, Shahid Behesti University of Medical Sciences0 个研究点目标入组 12 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • patients with mean pulmonary arterial pressure (mPAP) =25 mmHg (confirmed by catheterization at diagnosis time) and symptomatic pulmonary arterial hypertension (PAH) diagnosis
  • functional class (FC) II or III according to the world health organization classification
  • ages between 18 and 75 years old
  • 6-minute walk test (6-MWT) distance of 50 to 450 m
  • patients receiving stable treatments for PAH, the phosphodiesterase-5 inhibitors or the endothelin-receptor antagonist (bosentan) or both at a dose, and were being stable clinical and hemodynamical status for at least 3 months before randomization
  • use of anticoagulants, calcium channel blocker and diuretics will be allowed when the medicine or dosage was unchanged for at least last 3 months

排除标准

  • SSRIs, CCBs, MAOIs, sedatives, hypnotics, and alcohol consumers
  • patients who sleepiness and drowsiness are associated with hazards in their jobs
  • pregnancy and lactation
  • symptomatic prostate hypertrophy
  • CKD ( SCr.2.5, proteinuria>500mg/d)
  • angle-closure glaucoma

研究者

发起方
Faculty of Pharmacy, Shahid Behesti University of Medical Sciences

相似试验